Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Retension Pharmaceuticals, Inc. (RTSN : NSDQ)

• Company Description    Retension Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company's lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension. Retension Pharmaceuticals Inc. is based in FALLS CHURCH, Va. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $15.00 Daily Weekly Monthly 20 Day Moving Average: 222,017 shares Shares Outstanding: 8.33 (millions) Market Capitalization: $124.97 (millions) Beta: 52 Week High: $18.64 52 Week Low: $9.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1104 WEST BROAD STREET SUITE 1029 - FALLS CHURCH,VA 22046 USA ph: 703-940-9761 fax: - investors@retensionpharmaceuticals.com http://www.retensionpharmaceuticals.com

• General Corporate Information    Officers Eric Keller - Chief Executive Officer Michael Joseph Berendt - Chairman Sabine Bisson - Chief Operating Officer Alex Schwartz - Chief Financial Officer Franklin M. Berger - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76135H100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 8.33 Most Recent Split Date: (:1) Beta: Market Capitalization: $124.97 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - - ROA 09/30/26 - - 06/30/26 - - 03/31/26 - - Current Ratio 09/30/26 - - 06/30/26 - - 03/31/26 - - Quick Ratio 09/30/26 - - 06/30/26 - - 03/31/26 - - Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - - 03/31/26 - - Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - -

Powered by Zacks Investment Research ©